Navigation Links
Neurocrine Biosciences Reports First Quarter 2008 Results
Date:4/30/2008

mpany focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related diseases and disorders. Indiplon was licensed from DOV Pharmaceuticals in 1998. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's GnRH program and R & D pipeline and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's GnRH program include, but are not limited to, risk that the Company's elagolix Phase II clinical trials will fail to demonstrate that elagolix is safe and effective; risk that elagolix will not proceed to later stage clinical trials; risk associated with the Company's dependence on corporate collaborators for development, commercial manufacturing and marketing and sales activities. In addition, the Company faces risks and uncertainties with respect to the Company's R & D pipeline including risk that the Company's research stage GnRH receptor antagonists, urocortin 2, and CRF1 receptor antagonist will not proceed to later stage clinical trials. Risks associated with the Company's indiplon program include, but are not limited to risk that indiplon approval and subsequent commercialization may be indefinitely delayed or ne
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
3. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
4. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
5. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
6. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
7. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
8. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
9. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
10. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
11. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... SCHOFIELD, Wis. , July 30, 2014 /PRNewswire/ ... researcher, developer, and marketer of over-the-counter (OTC) medicinal ... is rebranding the LipiGesic ® M name along with ... will be replaced with the trademarked name MigraPure ... and color palette of PuraMed,s homeopathic, natural migraine ...
(Date:7/30/2014)... 30, 2014  El Camino Hospital, a leader in ... utilizing the Leaf Patient Monitoring system to help prevent ... of patients susceptible to bed sores. The ... study of the system, which showed dramatic improvement in ... regularly is the one of the most effect ways ...
(Date:7/30/2014)... -- InnoPharma, Inc. today announced the first generic launch of ... injection), in Canada.  Olanzapine is indicated for the rapid ... schizophrenia or bipolar I mania. As the ... into an agreement with Sandoz Canada Inc., pursuant to ... market and distribute Olanzapine Injection in Canada ...
Breaking Medicine Technology:PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 3El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 2Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 3Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 4Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 5Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 6Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 7Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 8Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 9Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 10Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 11Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 12Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 13Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 14Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 15Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 16Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 17Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 18Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 19Zargis StethAssist & Zargis Cardioscan Cleared for Sale in Australia 2Zargis StethAssist & Zargis Cardioscan Cleared for Sale in Australia 3Zargis StethAssist & Zargis Cardioscan Cleared for Sale in Australia 4Zargis StethAssist & Zargis Cardioscan Cleared for Sale in Australia 5Zargis StethAssist & Zargis Cardioscan Cleared for Sale in Australia 6
(Date:7/30/2014)... to artemisinin, the main drug to treat malaria, ... Plasmodium falciparum ( P. falciparum ) ... caused by a genetic mutation in the parasites. ... opposed to a standard three-day coursehas proved highly ... findings published today in the New England ...
(Date:7/30/2014)... Steven Reinberg HealthDay Reporter ... in the United States, at least 2,000 Americans die from ... Wednesday. Heat waves, heat stroke or sun stroke caused ... 2006 and 2010, according to the U.S. Centers for Disease ... severe loss of body heat -- accounted for 63 percent ...
(Date:7/30/2014)... It can happen in an instant: A small child pulls ... gets critically injured when the furniture tips over. "Every ... their homes and imagine what could tip over, fall off ... it becoming a reality," Dr. Alex Rosenau, president of the ... release. Between 2009 and 2011, roughly 43,000 people ended ...
(Date:7/30/2014)... 2014 SF Cable, distributor of the ... prices on the internet with guaranteed customer satisfaction announces ... and two colors. These lightning cords are MFI certified ... high quality SF Cable Lightning to USB Cables ... delivering faster charging and syncing. Compatible with the iPhone ...
(Date:7/30/2014)... York, New York (PRWEB) July 30, 2014 ... from uncontrollable brain bleeding has filed a Xarelto lawsuit ... by the blood thinner, Bernstein Liebhard LLP reports. According ... Court for the District of Vermont on July 25th, ... days when he suffered an irreversible brain bleed that ...
Breaking Medicine News(10 mins):Health News:Resistance to key malaria drug spreading at alarming rate in Southeast Asia 2Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 2Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 3Health News:Tip-Over Furniture Can Kill Kids 2Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3
... to impact the lives of one million families by ... Calif., Feb. 9 Shaklee Corporation Chairman and CEO ... an opportunity that offers economic support to one million ... York City, NY on Feb. 10."Families are struggling to ...
... Burn Awareness Campaign to Teach Families How to Avoid This ... New research conducted by the national nonprofit Home Safety Council ... percent) agree that there are actions they could take to ... (44 percent) say they haven,t done so because they don,t ...
... opioid drugs can pose risks even for patients, agency ... U.S. Food and Drug Administration announced plans Monday to ... by requiring manufacturers of certain opioid drugs to help ... the medications. , The FDA said it has sent ...
... disease, cancer , , MONDAY, Feb. 9 (HealthDay News) -- ... researchers find no evidence that multivitamin use helps older ... two killers of women, respectively. , "Women can be ... do no harm, but they also seem to confer ...
... Global Prevention Network(TM) as New York AffiliateDALLAS and NEW ... the leader in disease prevention services, has signed an ... jointly participate in preventive medicine programs in New York ... New York affiliate in The Global Prevention Network (TM) ...
... The Department of Veterans Affairs (VA) is calling for ... -- from March 8 to 14 at all medical centers ... standards for patient safety."The safety of our patients is our ... Under Secretary for Health. "Therefore, I am ordering all of ...
Cached Medicine News:Health News:Shaklee Hits the Road with its Infinite Possibilities Tour in New York, NY 2Health News:American Families Unaware of Burn Dangers at Home 2Health News:American Families Unaware of Burn Dangers at Home 3Health News:American Families Unaware of Burn Dangers at Home 4Health News:FDA Seeks Better Regulation of Painkillers 2Health News:Vitamins Do Older Women Little Good 2Health News:Vitamins Do Older Women Little Good 3Health News:U.S. Preventive Medicine(R), The Mount Sinai Medical Center Sign Affiliation Agreement to Jointly Deliver Preventive Medicine Services 2Health News:U.S. Preventive Medicine(R), The Mount Sinai Medical Center Sign Affiliation Agreement to Jointly Deliver Preventive Medicine Services 3
... Small Bone Power System combines precision ... under the most exacting conditions. The ... small bone osteotomies and oral/maxillofacial procedures ... Length Available), Oscillating Saw (Extended Length ...
... The Hall® Surgical E9000® System ... offers multiple electric handpieces specifically designed ... and Oral/Maxillofacial Surgery. The E9000 System ... console and 3 specialized handpieces designed ...
... USA™ Battery Tester is ... efficiently determine if your ... Extended Run, Stryker® 2115, ... Packs contain adequate charge ...
... offers a comprehensive line of high speed ... piece construction method that minimizes breakage. Using ... polished to create the sharpest edge possible, ... procedure., ,Our high speed cutters come ...
Medicine Products: